APGE

Apogee Therapeutics, Inc. Common Stock

$82.14 +5.55%

Recent alerts on APGE

All signals →

News Apogee falls following phase 2 results for zumilokibart in atopic dermatitis

News Apogee secures up to $1.3B from Blackstone to advance skin therapy

SEC filing APGE Secures $1.3B Strategic Financing from Blackstone, Advances Zumilokibart to Phase 3, $1.3B Total Cash Positioned for Self-Sustainability

News Blackstone Injecting Up to $1.3 Billion in Apogee for Skin Drug

News Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

News Apogee Therapeutics CMO sells over $225k in company stock By Investing.com - Investing.com Australia

News Apogee Therapeutics CEO sells shares worth over $558k By Investing.com - Investing.com Australia

Insider trade Sale by HENDERSON MICHAEL THOMAS (Chief Executive Officer)

SEC filing APGE Reports $1.3B Cash Position, Advances Zumilokibart Pipeline, $403M Equity Raise, Phase 3 AD Trials Expected H2 2026

Insider trade Sale by Carl Dambkowski (Chief Medical Officer)

Insider trade Sale by Jane Henderson (Chief Financial Officer)

SEC filing APGE Board Resignations: Gottesdiener, Harwin Step Down Effective May 11, 2026, Reducing Directors to Seven

Insider trade Sale by Jane Henderson (Chief Financial Officer)

Insider trade Sale by Michael Thomas Henderson (Chief Executive Officer)

News Apogee Therapeutics prices upsized $350M offering at $70 a share

News Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis

SEC filing APGE Announces Positive 52-Week Zumilokibart Data, 75% EASI-75, 86% vIGA 0/1, 6-Month Dosing, 2Q 2026 Phase 3 Readout, 2026 AAD Presentation

Insider trade Sale by Michael Thomas Henderson (Chief Executive Officer)

Insider trade Sale by Carl Dambkowski (Chief Medical Officer)

Insider trade Sale by Jane Henderson (Chief Financial Officer)

News Apogee Therapeutics reports FY results

SEC filing APGE Reports $902.9M Cash, $214.7M R&D Spend, Advances Zumilokibart AD Phase 3 2H 2026

Insider trade Sale by Michael Thomas Henderson (Chief Executive Officer)

Insider trade Sale by Carl Dambkowski (Chief Medical Officer)

Insider trade Sale by Jane Henderson (Chief Financial Officer)

Get push alerts for APGE

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS